title: Drug competition for intracellular triiodothyronine-binding sites.
abstract: A variety of substances, including frusemide, non-esterified fatty acids (NEFAs) and non-steroidal anti-inflammatory drugs (NSAIDs), can compete for triiodothyronine (T3)-binding sites in serum and at the cell surface. We examined the competitive potency of these agents at intracellular T3-binding sites in order to assess their potential to act as T3 antagonists. Competition for [125I]T3 binding was determined using hydroxyapatite separation in cytosols and nuclear extracts prepared from livers of Macaca fascicularis. The T3 affinities were 15.8 +/- 1.2 nmol/l in cytosol and 0.23 +/- 0.02 nmol/l in nuclear extract. Dose-response curves were analysed by a four-parameter sigmoid curve-fitting program to determine competitor potency. The nineteen agents tested included various NSAIDs, NEFAs, non-bile acid cholephils (NBACs), frusemide, amiodarone and the flavonoid EMD 21388. In nuclear extract the most active competitors were linoleic acid (8.5 mumol/l) and linolenic acid (7.8 mumol/l). Potencies of NSAIDs varied between 66 mumol/l (meclofenamic acid) and 525 mumol/l (diclofenac). In cytosol, NEFAs were less potent but NSAIDs were stronger competitors than in nuclear extract. Half-inhibitory potencies in cytosol were between 13.2 mumol/l (meclofenamic acid) and 63.1 mumol/l (flufenamic acid). The NBAC bromosulphthalein was one of the most potent inhibitors in both cytosol and nuclear extract. When expressed relative to T3, diclofenac was a more effective competitor in cytosol than it was in nuclear extract. Amiodarone and EMD 21388 were without effect both in cytosol and nuclear extract. Frusemide (759 mumol/l) was weakly active in cytosol only.(ABSTRACT TRUNCATED AT 250 WORDS)
authors.affiliation: Ewen Downie Metabolic Unit, Alfred Hospital, Melbourne, Victoria, Australia.
authors.forename: J W
authors.initials: JW
authors.lastname: Barlow
authors.forename: A J
authors.initials: AJ
authors.lastname: Curtis
authors.forename: L E
authors.initials: LE
authors.lastname: Raggatt
authors.forename: N M
authors.initials: NM
authors.lastname: Loidl
authors.forename: D J
authors.initials: DJ
authors.lastname: Topliss
authors.forename: J R
authors.initials: JR
authors.lastname: Stockigt
mesh_terms: D000638:Amiodarone / Q000378:metabolism; D000818:Animals; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000378:metabolism; D001665:Binding Sites; D001667:Binding, Competitive; D006528:Carcinoma, Hepatocellular / Q000378:metabolism; D005230:Fatty Acids, Nonesterified / Q000378:metabolism; D005419:Flavonoids / Q000378:metabolism; D005665:Furosemide / Q000378:metabolism; D006801:Humans; D007453:Iodide Peroxidase / Q000037:antagonists & inhibitors; D008099:Liver / Q000378:metabolism*; D008113:Liver Neoplasms / Q000378:metabolism; D008252:Macaca fascicularis; D012738:Sex Hormone-Binding Globulin / Q000378:metabolism; D013448:Sulfobromophthalein / Q000378:metabolism; D014284:Triiodothyronine / Q000378:metabolism* / Q000494:pharmacology; D014407:Tumor Cells, Cultured
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; D005230:Fatty Acids, Nonesterified; D005419:Flavonoids; D012738:Sex Hormone-Binding Globulin; D014284:Triiodothyronine; D013448:Sulfobromophthalein; C057452:3-methyl-4',6-dihydroxy-3',5'-dibromoflavone; D005665:Furosemide; D007453:Iodide Peroxidase; D000638:Amiodarone